Salix Pharmaceuticals, Ltd. Announces Issuance of U.S. Patent for Rifaximin

RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 7,452,857. This patent provides protection until August 2019.
MORE ON THIS TOPIC